2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
24
Lung Neoplasms
14
Carcinoma, Medullary
14
Neoplasm Metastasis
12
Neoplasms
10
Thyroid Neoplasms
8
Breast Neoplasms
8
Glioma
6
Prostatic Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Gliosarcoma
4
Colorectal Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion
2
Kidney Neoplasms
2
Familial medullary thyroid carcinoma
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Disease Progression
2
Interventions
midostaurin
2
vandetanib
1
selinexor
1
pegfilgrastim
1
glofitamab
1
Topotecan
1
Rituximab
1
Prednisone
1
Positron Emission Tomography Computed Tomography
1
Paclitaxel
1
Methylprednisolone
1
Immunologic Techniques
1
Ifosfamide
1
Flow Cytometry
1
Etoposide
1
Dexamethasone
1
Clofarabine
1
Carboplatin
1
Bexarotene
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Aggression
×
vandetanib
×
Clear all
NCT01945762
2024-12-18
Caprelsa104
Sanofi
Completed
31 enrolled